Drugs / FS118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03440437 | Apr 2018 → Jun 2024 | cancer of unknown primary site, head and neck squamous cell carcinoma, metastatic malignant neoplasm | invoX Pharma Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03440437 ↗ |
| Route | Intravenous | “received intravenous FS118 weekly” PMID 36342102 ↗ Mar 2023 |